Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 3/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | UBE2N | P61088 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14923117 | 0.93 | AURKA (0.48) | TNK2CHEK1DYRK1AAURKAALDH1A1 | |
| SCHEMBL6198726 | 0.92 | PDPK1 (0.50) | TNK2CHEK1DYRK1AAURKAALDH1A1 | |
| SCHEMBL6200114 | 0.92 | LMNA (0.47) | TNK2CHEK1DYRK1AAURKAALDH1A1 | |
| SCHEMBL1785591 | 0.89 | TNK2 (0.43) | TNK2CHEK1AURKAALDH1A1HPGD | |
| SCHEMBL1786338 | 0.89 | KDM4E (0.61) | TNK2CHEK1AURKAALDH1A1HPGD | |
| SCHEMBL6203015 | 0.88 | KDR (0.43) | TNK2CHEK1DYRK1AAURKAALDH1A1 | |
| SCHEMBL6202380 | 0.86 | NPC1 (0.43) | TNK2CHEK1DYRK1AAURKAALDH1A1 | |
| SCHEMBL12677063 | 0.85 | AKT1 (0.44) | TNK2 | |
| SCHEMBL2968444 | 0.84 | DYRK1A (0.44) | DYRK1AALDH1A1HPGDHSD17B10TSHR | |
| SCHEMBL2966057 | 0.84 | DYRK1A (0.48) | DYRK1AALDH1A1HPGDHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190212343-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20170299599-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | 2017-10-19 | — | — | US | disclosed |
| US-20170299599-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | 2017-10-19 | — | — | US | disclosed |
| US-9594084-B2 | Phosphorylation of histones and uses thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2017-03-14 | — | — | US | disclosed |
| US-9594084-B2 | Phosphorylation of histones and uses thereof | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| US-20160091498-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-31 | — | — | US | disclosed |
| US-20160091498-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2016-03-31 | — | — | US | disclosed |
| US-20150011567-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE | 2015-01-08 | — | — | US | disclosed |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-13 | — | — | US | disclosed |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-13 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2009134658-A2 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134658-A2 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | WO | disclosed |
| WO-2008131859-A2 | USE OF CYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008131859-A2 | USE OF CYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2007079861-A1 | NOVEL, CYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | AURKB, AURKA, AURKC | TNK2 193/4885CHEK1 45/4885DYRK1A 398/4885 |
| US-20170299599-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H1-3, H1-4, H1-5 | TNK2 456/4885CHEK1 451/4885DYRK1A 269/4885 |
| US-20150011567-A1 | PHOSPHORYLATION OF HISTONES AND USES THEREOF | H1-3, H1-4, H1-5 | TNK2 456/4885CHEK1 451/4885DYRK1A 269/4885 |
| US-20190212343-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | HNRNPH3, EP300, KAT2A | TNK2 413/4885CHEK1 440/4885DYRK1A 3249/4885 |
| US-20160091498-A1 | METHODS FOR THE TREATMENT OF DISORDERS RELATED TO PHOSPHORYLATION OF HISTONES | HNRNPH3, EP300, KAT2A | TNK2 413/4885CHEK1 440/4885DYRK1A 3249/4885 |
| US-20100120805-A1 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors | ERBB2, EGFR, BMX | TNK2 118/4885CHEK1 145/4885DYRK1A 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.